Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 2/20 | 0.32 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19658254 | 1.00 | PSMB8 (0.32) | PSMB8PSMB5ALOX12MGLL | |
| SCHEMBL19658247 | 1.00 | PSMB8 (0.32) | PSMB8PSMB5ALOX12MGLL | |
| SCHEMBL17776321 | 1.00 | PSMB8 (0.32) | PSMB8PSMB5ALOX12MGLL | |
| SCHEMBL13635161 | 1.00 | PSMB8 (0.32) | PSMB8PSMB5ALOX12MGLL | |
| SCHEMBL18751700 | 1.00 | PSMB8 (0.32) | PSMB8PSMB5ALOX12MGLL | |
| SCHEMBL17776273 | 1.00 | PSMB8 (0.32) | PSMB8PSMB5ALOX12MGLL | |
| SCHEMBL17776275 | 1.00 | PSMB8 (0.32) | PSMB8PSMB5ALOX12MGLL | |
| SCHEMBL10086616 | 1.00 | PSMB8 (0.32) | PSMB8PSMB5ALOX12MGLL | |
| SCHEMBL17776322 | 1.00 | PSMB8 (0.32) | PSMB8PSMB5ALOX12MGLL | |
| SCHEMBL29687696 | 1.00 | PSMB8 (0.32) | PSMB8PSMB5ALOX12MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4634205-A2 | CYCLIC PEPTIDES AS PET IMAGING AGENTS OF GRANZYME B | Merck Sharp & Dohme LLC (US) | 2025-10-22 | — | — | EP | disclosed |
| CN-120136959-A | Targeting compound, nuclide marker thereof, pharmaceutical composition containing same and application | 潍坊市人民医院(潍坊市公共卫生临床中心、潍坊市职业病医院) | 2025-06-13 | — | — | CN | disclosed |
| WO-2025078841-A2 | ANTIBODIES, CONJUGATES, AND USES THEREOF | ANTIKOR BIOPHARMA LIMITED (GB) | 2025-04-17 | — | — | WO | disclosed |
| US-20250114441-A1 | POLYMERIC VACCINE FOR OPIOID ADDICTION | THE JOHNS HOPKINS UNVERSITY | 2025-04-10 | — | — | US | disclosed |
| CN-119666793-A | Method for detecting and/or screening target protein expression cell line based on fluorescence indication | 中国科学院大连化学物理研究所 | 2025-03-21 | — | — | CN | disclosed |
| WO-2024129479-A2 | CYCLIC PEPTIDES AS PET IMAGING AGENTS OF GRANZYME B | MERCK SHARP & DOHME LLC (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20230398228-A1 | ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | EISAI R&D MAN CO LTD (JP) | 2023-12-14 | — | — | US | disclosed |
| US-20230398228-A1 | ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | EISAI R&D MAN CO LTD (JP) | 2023-12-14 | — | — | US | disclosed |
| US-20230398228-A1 | ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | EISAI R&D MAN CO LTD (JP) | 2023-12-14 | — | — | US | disclosed |
| US-20230310551-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME LLC (US) | 2023-10-05 | — | — | US | disclosed |
| US-20120178711-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | CERULEAN PHARMA INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120114658-A1 | TREATMENT OF CANCER | CERULEAN PHARMA INC. | 2012-05-10 | — | — | US | disclosed |
| US-20120064107-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | CERULEAN PHARMA INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065368-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | CERULEAN PHARMA INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120064071-A1 | TREATMENT OF CANCER | CERULEAN PHARMA INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-8110179-B2 | Cyclodextrin-based polymers for therapeutics delivery | CERULEAN PHARMA INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-20110245201-A1 | TREATMENT OF CANCER | CERULEAN PHARMA INC. | 2011-10-06 | — | — | US | disclosed |
| US-20110160159-A1 | TREATMENT OF CANCER | CERULEAN PHARMA INC. | 2011-06-30 | — | — | US | disclosed |
| US-20080058427-A1 | Cyclodextrin-based polymers for therapeutics delivery | INSERT THERAPEUTICS, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| US-7270808-B2 | Having covalently coupled bioactive agent and targeting ligand; controlled release; stability, solubility; reduced toxicity | INSERT THERAPEUTICS, INC. (US) | 2007-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120114658-A1 | TREATMENT OF CANCER | TOP1, TOP2A, TOP2B | PSMB8 1967/4885PSMB5 767/4885ALOX12 2835/4885 |
| US-20080058427-A1 | Cyclodextrin-based polymers for therapeutics delivery | DDOST, DSC1, SI | PSMB8 1891/4885PSMB5 1467/4885ALOX12 4379/4885 |
| US-20120178711-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | DDOST, DSC1, SI | PSMB8 1891/4885PSMB5 1467/4885ALOX12 4379/4885 |
| US-20120065368-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | DDOST, DSC1, SI | PSMB8 1891/4885PSMB5 1467/4885ALOX12 4379/4885 |
| US-20120064107-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | PHOSPHO1, SGMS1, SGMS2 | PSMB8 1513/4885PSMB5 1149/4885ALOX12 1749/4885 |
| US-20230398228-A1 | ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | FOLR1, FOLR2, TUBB1 | PSMB8 853/4885PSMB5 411/4885ALOX12 4373/4885 |
| US-20120064071-A1 | TREATMENT OF CANCER | TOP1, TOP2A, TOP2B | PSMB8 1967/4885PSMB5 767/4885ALOX12 2835/4885 |
| US-20250114441-A1 | POLYMERIC VACCINE FOR OPIOID ADDICTION | OPRM1, OPRK1, OPRL1 | PSMB8 908/4885PSMB5 1149/4885ALOX12 2426/4885 |
| US-20110160159-A1 | TREATMENT OF CANCER | TOP1, TOP2A, TOP2B | PSMB8 1967/4885PSMB5 767/4885ALOX12 2835/4885 |
| US-20110245201-A1 | TREATMENT OF CANCER | TOP1, TOP2A, TOP2B | PSMB8 1967/4885PSMB5 767/4885ALOX12 2835/4885 |
| US-20230310551-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | PSMB8 621/4885PSMB5 1651/4885ALOX12 4142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.